JP2018510207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510207A5 JP2018510207A5 JP2017560843A JP2017560843A JP2018510207A5 JP 2018510207 A5 JP2018510207 A5 JP 2018510207A5 JP 2017560843 A JP2017560843 A JP 2017560843A JP 2017560843 A JP2017560843 A JP 2017560843A JP 2018510207 A5 JP2018510207 A5 JP 2018510207A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- condition
- compound according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 90
- 150000001875 compounds Chemical class 0.000 claims 54
- 201000010099 disease Diseases 0.000 claims 48
- 208000035475 disorder Diseases 0.000 claims 42
- 230000002265 prevention Effects 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 23
- 239000012453 solvate Substances 0.000 claims 23
- -1 perhaloalkyl Chemical group 0.000 claims 22
- 229940002612 prodrug Drugs 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 208000011580 syndromic disease Diseases 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 9
- 206010061218 Inflammation Diseases 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 208000027866 inflammatory disease Diseases 0.000 claims 8
- 230000004054 inflammatory process Effects 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- 208000017520 skin disease Diseases 0.000 claims 6
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 4
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 4
- 208000035690 Familial cold urticaria Diseases 0.000 claims 4
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims 4
- 206010072219 Mevalonic aciduria Diseases 0.000 claims 4
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 4
- 206010031252 Osteomyelitis Diseases 0.000 claims 4
- 210000000068 Th17 cell Anatomy 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 230000008938 immune dysregulation Effects 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 230000000737 periodic effect Effects 0.000 claims 4
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 208000012414 A20 haploinsufficiency Diseases 0.000 claims 2
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 2
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000022210 Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 201000009182 Chikungunya Diseases 0.000 claims 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010061788 Corneal infection Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 108700036803 Deficiency of interleukin-1 receptor antagonist Proteins 0.000 claims 2
- 208000001490 Dengue Diseases 0.000 claims 2
- 206010012310 Dengue fever Diseases 0.000 claims 2
- 241000710829 Dengue virus group Species 0.000 claims 2
- 206010012559 Developmental delay Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 241001475178 Dira Species 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000006968 Helminthiasis Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020633 Hyperglobulinaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000006311 Pyoderma Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 208000010265 Sweet syndrome Diseases 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 241000907316 Zika virus Species 0.000 claims 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 208000007474 aortic aneurysm Diseases 0.000 claims 2
- 206010003441 asbestosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000025255 bacterial arthritis Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 2
- 150000004697 chelate complex Chemical class 0.000 claims 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 208000024858 congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 208000025729 dengue disease Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000000750 endocrine system Anatomy 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 201000005033 granulomatous angiitis Diseases 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 208000004593 pneumococcal meningitis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000005956 sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay Diseases 0.000 claims 2
- 230000037432 silent mutation Effects 0.000 claims 2
- 230000000392 somatic effect Effects 0.000 claims 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 150000003852 triazoles Chemical class 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 0 *c(c1c2***1)c(***1)c1c2NC(NSC1**B[*+]1)=O Chemical compound *c(c1c2***1)c(***1)c1c2NC(NSC1**B[*+]1)=O 0.000 description 3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131251A JP7566699B2 (ja) | 2015-02-16 | 2021-08-11 | スルホニル尿素及び関連化合物並びにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015900507A AU2015900507A0 (en) | 2015-02-16 | Sulfonylureas and related compounds and use of same | |
| AU2015900507 | 2015-02-16 | ||
| PCT/AU2016/050103 WO2016131098A1 (en) | 2015-02-16 | 2016-02-16 | Sulfonylureas and related compounds and use of same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131251A Division JP7566699B2 (ja) | 2015-02-16 | 2021-08-11 | スルホニル尿素及び関連化合物並びにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510207A JP2018510207A (ja) | 2018-04-12 |
| JP2018510207A5 true JP2018510207A5 (enExample) | 2019-03-28 |
| JP6929792B2 JP6929792B2 (ja) | 2021-09-01 |
Family
ID=56691944
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560843A Active JP6929792B2 (ja) | 2015-02-16 | 2016-02-16 | スルホニル尿素及び関連化合物並びにその使用 |
| JP2021131251A Active JP7566699B2 (ja) | 2015-02-16 | 2021-08-11 | スルホニル尿素及び関連化合物並びにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131251A Active JP7566699B2 (ja) | 2015-02-16 | 2021-08-11 | スルホニル尿素及び関連化合物並びにその使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10538487B2 (enExample) |
| EP (3) | EP3259253B1 (enExample) |
| JP (2) | JP6929792B2 (enExample) |
| KR (2) | KR102727059B1 (enExample) |
| CN (3) | CN113563264A (enExample) |
| AU (3) | AU2016222278B2 (enExample) |
| CA (2) | CA2975192A1 (enExample) |
| CL (2) | CL2017002097A1 (enExample) |
| CY (1) | CY1122832T1 (enExample) |
| DK (2) | DK3578547T3 (enExample) |
| ES (2) | ES2881228T3 (enExample) |
| HR (2) | HRP20200214T1 (enExample) |
| HU (1) | HUE055755T2 (enExample) |
| IL (2) | IL253661B2 (enExample) |
| LT (2) | LT3578547T (enExample) |
| MA (3) | MA56473A (enExample) |
| MD (1) | MD3259253T2 (enExample) |
| ME (1) | ME03737B (enExample) |
| MX (2) | MX2017010528A (enExample) |
| MY (2) | MY193765A (enExample) |
| NZ (1) | NZ733948A (enExample) |
| PE (2) | PE20180160A1 (enExample) |
| PL (2) | PL3259253T3 (enExample) |
| PT (2) | PT3578547T (enExample) |
| RS (2) | RS60048B1 (enExample) |
| RU (1) | RU2739356C2 (enExample) |
| SG (2) | SG10202002599XA (enExample) |
| SI (2) | SI3259253T1 (enExample) |
| SM (1) | SMT202000192T1 (enExample) |
| WO (1) | WO2016131098A1 (enExample) |
Families Citing this family (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113563264A (zh) | 2015-02-16 | 2021-10-29 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| BR112018016671A2 (pt) * | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| US11597706B2 (en) | 2016-04-18 | 2023-03-07 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| WO2018103583A1 (en) * | 2016-12-05 | 2018-06-14 | Zibo Anxuan Pharmaceutical Science And Technology Co., Ltd. | N-hydroxy-benzene-sulfonamide derivatives and their uses thereof |
| CN110366549A (zh) * | 2017-01-23 | 2019-10-22 | 基因泰克公司 | 作为白介素-1活性抑制剂的化合物 |
| GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| CA3059458A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MA56075A (fr) * | 2017-07-07 | 2022-04-06 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| CN110914258A (zh) * | 2017-07-14 | 2020-03-24 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
| EP3658538B1 (en) * | 2017-07-24 | 2023-04-19 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| IL271259B2 (en) * | 2017-07-24 | 2024-06-01 | Novartis Inflammasome Res Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| WO2019034686A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| DE102017118230B4 (de) * | 2017-08-10 | 2021-04-22 | Christoph Lucks | Verfahren zur Analyse und/oder Überwachung von Brücken sowie entsprechendes System und entsprechende Verwendung |
| EP3668601A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019034688A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| WO2019034693A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| WO2019034697A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| EP3692020A1 (en) * | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| WO2019092172A1 (en) * | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| SG11202003984UA (en) * | 2017-11-09 | 2020-05-28 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019166619A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019166633A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| GB201803393D0 (en) * | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US20200399242A1 (en) * | 2018-03-02 | 2020-12-24 | Inflazome Limited | Novel compounds |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| WO2019166628A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019182981A1 (en) * | 2018-03-21 | 2019-09-26 | Olatec Therapeutics Llc | Methods for treating melanoma |
| EP3784658B1 (en) * | 2018-04-23 | 2025-08-20 | Corcept Therapeutics Incorporated | Methods of preparing regioselective n-alkyl triazoles |
| GB201806578D0 (en) * | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| WO2019211463A1 (en) | 2018-05-04 | 2019-11-07 | Inflazome Limited | Novel compounds |
| CN108404117B (zh) * | 2018-05-29 | 2020-06-30 | 广东龙帆生物科技有限公司 | 核苷酸结合寡聚化结构域样受体蛋白在治疗寨卡病毒感染药物中的应用 |
| JP2021529780A (ja) * | 2018-07-03 | 2021-11-04 | ノバルティス アーゲー | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
| US20220267276A1 (en) * | 2018-07-03 | 2022-08-25 | Novartis Ag | Nlrp modulators |
| WO2020010140A1 (en) * | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Nlrp modulators |
| WO2020018970A1 (en) * | 2018-07-20 | 2020-01-23 | Genentech, Inc. | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| KR20210034596A (ko) | 2018-07-20 | 2021-03-30 | 에프. 호프만-라 로슈 아게 | 인터류킨-1 활성의 저해제로서 술폰이미드아미드 화합물 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| BR112021002770A2 (pt) | 2018-08-15 | 2021-05-04 | Inflazome Limited | compostos inovadores de sulfonamidaurea |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (ja) * | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| CN113015730A (zh) * | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| LT3880660T (lt) * | 2018-11-13 | 2025-10-10 | Junginiai ir kompozicijos, skirti gydyti su nlrp veikla susijusia būkles | |
| JP2022506898A (ja) * | 2018-11-13 | 2022-01-17 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 |
| JP2022507505A (ja) * | 2018-11-16 | 2022-01-18 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| EP3880659B1 (en) * | 2018-11-16 | 2024-01-03 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| FI3911631T3 (fi) | 2019-01-14 | 2025-02-03 | Zydus Lifesciences Ltd | Uusia substituoituja sulfonyyliureajohdannaisia |
| EP3914583A1 (en) * | 2019-01-22 | 2021-12-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| JP2022518526A (ja) * | 2019-01-25 | 2022-03-15 | ノッドセラ リミテッド | カルバメート誘導体およびその使用 |
| CN113614063A (zh) | 2019-02-22 | 2021-11-05 | Pi工业有限公司 | 合成氨茴二酰胺化合物及其中间体的方法 |
| EP3934636A1 (en) * | 2019-03-06 | 2022-01-12 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Inhibitors of ngal protein |
| GB201905265D0 (en) * | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| CN111848461A (zh) * | 2019-04-29 | 2020-10-30 | 苏州大学 | Nlrp3炎症小体抑制剂及其制备方法和应用 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| PT3983387T (pt) | 2019-06-12 | 2024-07-10 | Nodthera Ltd | Derivados de sulfonilurea e seus usos |
| US20220267300A1 (en) * | 2019-06-12 | 2022-08-25 | NodThera Limited | Sulfonamide derivatives and uses thereof |
| WO2020254697A1 (en) | 2019-06-21 | 2020-12-24 | Ac Immune Sa | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| KR20220064364A (ko) * | 2019-07-17 | 2022-05-18 | 조마젠 바이오사이언시즈 엘티디 | 다발성 경화증(ms)의 치료를 위한 nlpr3 조절제로서의 n-((1,2,3,5,6,7-헥사하이드로-s-인다센-4-일)카바모일)-4,5,6,7-테트라하이드로벤조푸란-2-설폰아미드 유도체 및 관련 화합물 |
| KR102852270B1 (ko) * | 2019-07-17 | 2025-08-29 | 조마젠 바이오사이언시즈 엘티디 | Nlrp3 조절제 |
| US20220289766A1 (en) * | 2019-08-16 | 2022-09-15 | Inflazome Limited | Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors |
| JP2022547882A (ja) * | 2019-09-06 | 2022-11-16 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤 |
| CN114746087A (zh) | 2019-09-12 | 2022-07-12 | 载度思生命科学有限公司 | 新的经取代的亚砜亚胺衍生物 |
| WO2021089781A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
| CN114599356A (zh) * | 2019-11-07 | 2022-06-07 | 英夫拉索姆有限公司 | 自身炎症性病症的治疗 |
| GB201916237D0 (en) * | 2019-11-07 | 2019-12-25 | Inflazome Ltd | Novel treatment |
| WO2021089768A2 (en) | 2019-11-07 | 2021-05-14 | Inflazome Limited | Novel treatment |
| CN114630664A (zh) * | 2019-11-07 | 2022-06-14 | 英夫拉索姆有限公司 | 神经炎症或炎性脑部病症的治疗和预防 |
| WO2021089776A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment and prevention of a traumatic brain disorder |
| AU2020383646B2 (en) * | 2019-11-12 | 2023-10-12 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Amide derivative and preparation method therefore and use thereof in medicine |
| WO2021111351A1 (en) * | 2019-12-03 | 2021-06-10 | Cadila Healthcare Limited | Novel substituted sulfonylurea and sulfoximineurea derivatives |
| IL294536A (en) * | 2020-01-22 | 2022-09-01 | Hoffmann La Roche | Sulfonimidamide compounds as nlrp3 modulators |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2021165245A1 (en) | 2020-02-18 | 2021-08-26 | Inflazome Limited | Compounds |
| CN115605209B (zh) | 2020-03-16 | 2024-12-17 | 祖玛珍生物科学有限公司 | Nlrp3调节剂 |
| CN111358778A (zh) * | 2020-03-17 | 2020-07-03 | 中国医科大学附属第一医院 | Mcc950在制备预防或治疗阿尔茨海默病的药物中的应用 |
| EP4121032A1 (en) | 2020-03-19 | 2023-01-25 | Softhale NV | Method for the treatment nlrp3-associated diseases |
| US20230183249A1 (en) * | 2020-04-30 | 2023-06-15 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| CN115768749B (zh) * | 2020-06-11 | 2024-04-19 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物 |
| IL299084A (en) * | 2020-06-19 | 2023-02-01 | Ac Immune Sa | History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway |
| WO2022022646A1 (zh) * | 2020-07-29 | 2022-02-03 | 南京明德新药研发有限公司 | 含硒五元杂芳环化合物 |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| EP4208459A1 (en) * | 2020-09-04 | 2023-07-12 | Nodthera Limited | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof |
| US20250073218A1 (en) * | 2020-11-04 | 2025-03-06 | Uppthera | Nlrp3 protein degradation inducing compound |
| FR3115682B1 (fr) * | 2020-11-05 | 2023-02-24 | Roquette Freres | Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique |
| WO2022104102A2 (en) * | 2020-11-13 | 2022-05-19 | University Of Miami | Materials and methods for treating corneal dysfunction |
| AU2021381396A1 (en) * | 2020-11-20 | 2023-06-22 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| EP4251630A4 (en) * | 2020-11-25 | 2024-12-11 | Venatorx Pharmaceuticals, Inc. | Sulfonyl urea nlrp3 inflammasome inhibitors |
| KR102802013B1 (ko) * | 2021-02-03 | 2025-05-07 | 환인제약 주식회사 | 알츠하이머병 치료를 위한 nlrp3 인플라마좀 소분자 억제제 |
| JP2024508728A (ja) * | 2021-02-10 | 2024-02-28 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| WO2022232632A1 (en) * | 2021-04-30 | 2022-11-03 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| IT202100011237A1 (it) * | 2021-05-03 | 2022-11-03 | Univ Degli Studi Di Torino | Composti inibitori dell’inflammasoma nlrp3 e loro uso |
| TW202246230A (zh) * | 2021-05-10 | 2022-12-01 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| TWI815439B (zh) * | 2021-05-10 | 2023-09-11 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| CN116635374B (zh) * | 2021-05-10 | 2025-05-06 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| IL308164A (en) | 2021-06-23 | 2023-12-01 | Hoffmann La Roche | CRYSTALLINE POTASSIUM SALT OF 1-ETHYL-N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)PIPERIDINE-4- SULFANAMIDE |
| ES2948511A1 (es) * | 2021-09-08 | 2023-09-13 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Derivados de n-sulfonilureas y su uso terapeutico |
| CN115894478B (zh) * | 2021-09-30 | 2025-04-04 | 杭州民生药物研究院有限公司 | 一种新型吡啶并吡唑类杂环化合物及其应用 |
| KR20230066899A (ko) | 2021-11-08 | 2023-05-16 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| CN118355000A (zh) * | 2021-12-03 | 2024-07-16 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| JP2025502732A (ja) | 2021-12-22 | 2025-01-28 | エーシー・イミューン・エス・アー | ジヒドロオキサゾール誘導体化合物 |
| WO2023230002A1 (en) * | 2022-05-23 | 2023-11-30 | VenatoRx Pharmaceuticals, Inc. | Nlrp3 inflammasome inhibitors |
| US20250388568A1 (en) * | 2022-07-06 | 2025-12-25 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| CA3261036A1 (en) | 2022-07-14 | 2024-01-18 | Ac Immune Sa | Pyrrolotriazine and imidazotriazine derivatives used as NLRP3 inflammatory pathway modulators |
| EP4562009A1 (en) | 2022-07-28 | 2025-06-04 | AC Immune SA | Novel compounds |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| KR20240022938A (ko) | 2022-08-12 | 2024-02-20 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN115772173B (zh) * | 2022-12-20 | 2024-04-16 | 武汉国粹医药科技有限公司 | 苯并呋喃类化合物、其制备方法及其应用和抗菌剂 |
| TW202502344A (zh) | 2023-06-02 | 2025-01-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之5,6不飽和雙環雜環 |
| KR20250030934A (ko) | 2023-08-25 | 2025-03-05 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025068958A1 (en) * | 2023-09-29 | 2025-04-03 | Novartis Ag | Nlrp3 inhibitor for use in lowering the risk of cardiovascular diseases |
| WO2025113692A1 (zh) * | 2023-12-01 | 2025-06-05 | 拜西欧斯（北京）生物技术有限公司 | 磺酰脲衍生物及其应用 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| CN120463630A (zh) * | 2024-02-09 | 2025-08-12 | 杭州矩阵生物药业有限公司 | 具有nlrp3抑制活性的磺酰脲类衍生物及其应用 |
| WO2026001614A1 (zh) * | 2024-06-26 | 2026-01-02 | 拜西欧斯（北京）生物技术有限公司 | 一种磺酰脲类化合物及其用途 |
| CN120535399A (zh) * | 2025-06-11 | 2025-08-26 | 上海麦克林生化科技股份有限公司 | 4-(2,2,2-三氟-1-烷氧基乙基)苯酚的制备方法 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB797474A (en) | 1955-07-20 | 1958-07-02 | Boehringer & Soehne Gmbh | Sulphonylurea derivatives |
| US3242174A (en) | 1962-02-06 | 1966-03-22 | Pfizer & Co C | 1-(tertiary aminosulfonyl)-3-(hydrocarbon) ureas |
| US3305556A (en) | 1962-11-23 | 1967-02-21 | Pfizer & Co C | Novel hypoglycemic agents |
| NL129208C (enExample) | 1965-07-14 | |||
| CH509992A (de) | 1966-08-08 | 1971-07-15 | Hoffmann La Roche | Verfahren zur Herstellung von Sulfonamiden |
| NL131473C (enExample) | 1966-10-28 | |||
| BE754588A (fr) | 1969-08-07 | 1971-02-08 | Hoechst Ag | Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances |
| FR2063472A5 (enExample) | 1969-10-17 | 1971-07-09 | Mercier Pierre | |
| GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| AU571869B2 (en) | 1983-05-09 | 1988-04-28 | E.I. Du Pont De Nemours And Company | Pyridyl- and pyrimidyl- sulphonamides |
| EP0126711B1 (de) | 1983-05-16 | 1989-08-02 | Ciba-Geigy Ag | Herbizid wirksame und pflanzenwuchsregulierende Pyrimidin-Derivate, deren Herstellung und Verwendung |
| JPS6045573A (ja) | 1983-08-22 | 1985-03-12 | Nissan Chem Ind Ltd | ピラゾ−ルスルホニルウレア誘導体，その製法および該誘導体を含有する選択性除草剤 |
| US4723991A (en) | 1984-03-23 | 1988-02-09 | E. I. Du Pont De Nemours And Company | Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity |
| US4659369A (en) | 1984-08-27 | 1987-04-21 | E. I. Du Pont De Nemours And Company | Herbicidal acetals and ketals |
| AU578307B2 (en) | 1984-09-17 | 1988-10-20 | E.I. Du Pont De Nemours And Company | Herbicidal pyrazolesulfonamides |
| FI855180L (fi) | 1985-01-18 | 1986-07-19 | Nissan Chemical Ind Ltd | Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift. |
| JPH0720957B2 (ja) | 1985-11-26 | 1995-03-08 | 日産化学工業株式会社 | ピラゾ−ルスルホニルウレア誘導体、製法および除草剤 |
| JP2570686B2 (ja) | 1985-12-23 | 1997-01-08 | 日産化学工業株式会社 | ピラゾ−ル誘導体 |
| US4830660A (en) | 1986-06-19 | 1989-05-16 | Nissan Chemical Industries, Ltd. | Imidazolesulfonamide derivatives and herbicides |
| EP0262096B1 (de) | 1986-09-26 | 1992-01-02 | Ciba-Geigy Ag | Aminopyrazinone und Aminotriazinone |
| US4802908A (en) | 1987-01-22 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2-(1H)-pyrazinones |
| WO1991010668A1 (en) | 1990-01-22 | 1991-07-25 | E.I. Du Pont De Nemours And Company | Herbicidal sulfonylureas |
| NZ238911A (en) | 1990-07-17 | 1993-10-26 | Lilly Co Eli | Furyl, pyrrolyl and thienyl sulphonyl urea derivatives, pharmaceutical compositions and intermediates therefor |
| AU647830B2 (en) | 1990-08-29 | 1994-03-31 | E.I. Du Pont De Nemours And Company | Herbicidal pyrrolesulfonylureas |
| US5214206A (en) * | 1990-11-07 | 1993-05-25 | Warner-Lambert Company | Aminosulfonyl urea acat inhibitors |
| DE4039733A1 (de) | 1990-12-13 | 1992-06-17 | Basf Ag | Substituierte 5-aminopyrazole |
| JPH06510762A (ja) | 1991-08-19 | 1994-12-01 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | アンジオテンシン２受容体遮断イミダゾリノン誘導体 |
| EP0601039A1 (en) | 1991-08-19 | 1994-06-15 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazolinone derivatives |
| US5169860A (en) * | 1992-03-13 | 1992-12-08 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| US5219856A (en) | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
| JPH0645573A (ja) | 1992-07-23 | 1994-02-18 | Nikon Corp | 赤外線固体撮像装置 |
| JPH06199053A (ja) | 1992-12-28 | 1994-07-19 | Sankyo Kagaku Kk | 感熱転写記録用色素 |
| JPH06199054A (ja) | 1992-12-28 | 1994-07-19 | Dainippon Printing Co Ltd | 熱転写シート |
| JPH06199047A (ja) | 1993-01-08 | 1994-07-19 | New Oji Paper Co Ltd | 感熱記録体 |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| AU7007696A (en) | 1995-09-22 | 1997-04-09 | E.I. Du Pont De Nemours And Company | Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines |
| WO1997011941A1 (fr) | 1995-09-28 | 1997-04-03 | Suntory Limited | Derives de la quinazoline et leurs emplois |
| AU1735497A (en) * | 1996-02-26 | 1997-09-10 | Sumitomo Pharmaceuticals Company, Limited | Sulfonylureidopyrazole derivatives |
| ATE242208T1 (de) * | 1997-01-29 | 2003-06-15 | Pfizer | Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität |
| US6022984A (en) | 1998-07-27 | 2000-02-08 | Pfizer Inc. | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors |
| JP2000053649A (ja) | 1998-08-11 | 2000-02-22 | Sumitomo Pharmaceut Co Ltd | スルホニルウレイドピラゾール誘導体 |
| EP0987552A3 (en) | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
| JP2002539191A (ja) | 1999-03-15 | 2002-11-19 | アクシス・ファーマシューティカルズ・インコーポレイテッド | プロテアーゼ阻害剤としての新規化合物及び組成物 |
| CA2383026A1 (en) * | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| DE60114994T2 (de) | 2000-02-04 | 2006-08-03 | Portola Pharmaceuticals, Inc., South San Francisco | Blutplättchen-adp-rezeptor-inhibitoren |
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| PL367093A1 (en) | 2001-05-18 | 2005-02-21 | Solvay Pharmaceuticals Gmbh | Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments |
| AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| FI110677B (fi) | 2001-10-12 | 2003-03-14 | Jujo Thermal Oy | Lämpöherkkä tallennusmateriaali |
| ATE355064T1 (de) | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| EP1487457A1 (en) | 2001-11-30 | 2004-12-22 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| JP2005538953A (ja) | 2002-05-28 | 2005-12-22 | ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド | 新規チオフェンアミジン、それらの組成物、および補体媒介疾患および病気を治療する方法 |
| CA2540214A1 (en) | 2003-10-03 | 2005-04-14 | Portola Pharmaceuticals, Inc. | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
| EP1667989A4 (en) | 2003-10-03 | 2008-08-20 | Portola Pharm Inc | SUBSTITUTED ISOQUINOLEINONES |
| WO2005105777A1 (en) * | 2004-05-05 | 2005-11-10 | Pharmacia & Upjohn Company Llc | Substituted thiophene amide compounds for the treatment of inflammation |
| EP1812429A4 (en) | 2004-09-29 | 2010-07-21 | Portola Pharm Inc | SUBSTITUTED 2H-1,3-BENZOXAZIN-4 (3H) -ONE |
| AR052900A1 (es) | 2005-02-11 | 2007-04-11 | Astrazeneca Ab | Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1 |
| GB0505539D0 (en) | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
| DK200600313A (da) | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
| CA2644368A1 (en) * | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
| GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| WO2009065096A1 (en) | 2007-11-16 | 2009-05-22 | University Of Medicine And Dentistry Of New Jersey | Mechanism-based small-molecule parasite inhibitors |
| US8211928B2 (en) * | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| CA2792102C (en) | 2010-03-05 | 2015-06-09 | Kyowa Hakko Kirin Co., Ltd. | Pyrazolopyrimidine derivative |
| US9557321B2 (en) * | 2010-11-18 | 2017-01-31 | Kyoto University | Method for screening drugs for suppressing inflammasome activity |
| KR20140075698A (ko) | 2011-09-02 | 2014-06-19 | 교와 핫꼬 기린 가부시키가이샤 | 케모카인 수용체 활성 조절제 |
| JP6036193B2 (ja) * | 2012-11-09 | 2016-11-30 | 国立大学法人富山大学 | インフラマソーム活性制御剤 |
| PL221813B1 (pl) | 2013-02-22 | 2016-05-31 | Univ Medyczny W Lublinie | Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania |
| TW201501713A (zh) | 2013-03-01 | 2015-01-16 | Kyowa Hakko Kirin Co Ltd | 眼炎症性疾病之預防及／或治療劑 |
| CN104513239B (zh) | 2014-12-10 | 2017-08-22 | 沈阳药科大学 | 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用 |
| WO2016119349A1 (zh) | 2015-01-29 | 2016-08-04 | 中国农业大学 | 一种磺酰脲类、磺酰胺基甲酸酯类化合物的制备方法 |
| CN113563264A (zh) * | 2015-02-16 | 2021-10-29 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| WO2016138473A1 (en) | 2015-02-26 | 2016-09-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
| WO2017106957A1 (en) | 2015-12-23 | 2017-06-29 | The University Of British Columbia | Lipid-linked prodrugs |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| EP3445749B1 (en) | 2016-04-18 | 2022-12-21 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
| CA3059458A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MA56075A (fr) | 2017-07-07 | 2022-04-06 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| WO2019034686A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| US12408224B2 (en) | 2018-09-27 | 2025-09-02 | Apple Inc. | Radio link monitoring and failure for new radio-unlicensed operation |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
-
2016
- 2016-02-16 CN CN202110865543.XA patent/CN113563264A/zh active Pending
- 2016-02-16 PE PE2017001395A patent/PE20180160A1/es unknown
- 2016-02-16 PT PT191871417T patent/PT3578547T/pt unknown
- 2016-02-16 MX MX2017010528A patent/MX2017010528A/es unknown
- 2016-02-16 CA CA2975192A patent/CA2975192A1/en active Pending
- 2016-02-16 MA MA056473A patent/MA56473A/fr unknown
- 2016-02-16 IL IL253661A patent/IL253661B2/en unknown
- 2016-02-16 SG SG10202002599XA patent/SG10202002599XA/en unknown
- 2016-02-16 CN CN201680010446.XA patent/CN107428696B/zh active Active
- 2016-02-16 JP JP2017560843A patent/JP6929792B2/ja active Active
- 2016-02-16 PE PE2021001430A patent/PE20221627A1/es unknown
- 2016-02-16 PT PT167518216T patent/PT3259253T/pt unknown
- 2016-02-16 SM SM20200192T patent/SMT202000192T1/it unknown
- 2016-02-16 KR KR1020177025608A patent/KR102727059B1/ko active Active
- 2016-02-16 MA MA41553A patent/MA41553B1/fr unknown
- 2016-02-16 MA MA47440A patent/MA47440B1/fr unknown
- 2016-02-16 IL IL273065A patent/IL273065B2/en unknown
- 2016-02-16 EP EP16751821.6A patent/EP3259253B1/en active Active
- 2016-02-16 RS RS20200258A patent/RS60048B1/sr unknown
- 2016-02-16 SI SI201630635T patent/SI3259253T1/sl unknown
- 2016-02-16 CA CA3250390A patent/CA3250390A1/en active Pending
- 2016-02-16 MY MYPI2017001188A patent/MY193765A/en unknown
- 2016-02-16 SI SI201631297T patent/SI3578547T1/sl unknown
- 2016-02-16 PL PL16751821T patent/PL3259253T3/pl unknown
- 2016-02-16 DK DK19187141.7T patent/DK3578547T3/da active
- 2016-02-16 AU AU2016222278A patent/AU2016222278B2/en active Active
- 2016-02-16 US US15/551,264 patent/US10538487B2/en active Active
- 2016-02-16 LT LTEP19187141.7T patent/LT3578547T/lt unknown
- 2016-02-16 PL PL19187141T patent/PL3578547T3/pl unknown
- 2016-02-16 CN CN202110867103.8A patent/CN113582889B/zh active Active
- 2016-02-16 ES ES19187141T patent/ES2881228T3/es active Active
- 2016-02-16 RS RS20210952A patent/RS62164B1/sr unknown
- 2016-02-16 MY MYPI2020001281A patent/MY197094A/en unknown
- 2016-02-16 ES ES16751821T patent/ES2777626T3/es active Active
- 2016-02-16 ME MEP-2020-49A patent/ME03737B/me unknown
- 2016-02-16 EP EP21152421.0A patent/EP3888749A1/en active Pending
- 2016-02-16 EP EP19187141.7A patent/EP3578547B1/en active Active
- 2016-02-16 NZ NZ733948A patent/NZ733948A/en unknown
- 2016-02-16 RU RU2017128287A patent/RU2739356C2/ru active
- 2016-02-16 LT LTEP16751821.6T patent/LT3259253T/lt unknown
- 2016-02-16 SG SG11201706664QA patent/SG11201706664QA/en unknown
- 2016-02-16 MD MDE20180009T patent/MD3259253T2/ro unknown
- 2016-02-16 DK DK16751821.6T patent/DK3259253T3/da active
- 2016-02-16 HR HRP20200214TT patent/HRP20200214T1/hr unknown
- 2016-02-16 WO PCT/AU2016/050103 patent/WO2016131098A1/en not_active Ceased
- 2016-02-16 HU HUE19187141A patent/HUE055755T2/hu unknown
- 2016-02-16 KR KR1020247036650A patent/KR20240162585A/ko active Pending
-
2017
- 2017-08-15 MX MX2023001647A patent/MX2023001647A/es unknown
- 2017-08-16 CL CL2017002097A patent/CL2017002097A1/es unknown
-
2019
- 2019-01-08 CL CL2019000060A patent/CL2019000060A1/es unknown
- 2019-08-07 US US16/535,002 patent/US11130731B2/en active Active
-
2020
- 2020-03-18 CY CY20201100252T patent/CY1122832T1/el unknown
- 2020-05-26 AU AU2020203464A patent/AU2020203464B2/en active Active
-
2021
- 2021-07-29 HR HRP20211225TT patent/HRP20211225T1/hr unknown
- 2021-08-11 JP JP2021131251A patent/JP7566699B2/ja active Active
- 2021-08-18 US US17/405,989 patent/US20220112159A1/en active Granted
- 2021-10-28 AU AU2021258033A patent/AU2021258033A1/en not_active Abandoned
-
2023
- 2023-12-14 US US18/540,743 patent/US20240400502A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510207A5 (enExample) | ||
| HRP20211225T1 (hr) | Sulfoniluree i srodni spojevi i njihova uporaba | |
| CN103492370B (zh) | 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法 | |
| JP2023040106A (ja) | 統合的ストレス経路のプロドラッグ調節剤 | |
| CN109789146B (zh) | 趋化因子受体调节剂及其用途 | |
| JP7335241B2 (ja) | 統合的ストレス経路の調節剤 | |
| TWI777014B (zh) | 可作為蛋白質調節劑之雜環醯胺 | |
| JP7184889B2 (ja) | 統合的ストレス経路の調節剤 | |
| ES2800026T3 (es) | Tratamiento de enfermedades inmunitarias e inflamatorias | |
| TW200819127A (en) | Novel receptor antagonists and their methods of use | |
| EA201001127A1 (ru) | Производные пиридина | |
| EA201001129A1 (ru) | Пиримидины в качестве ингибиторов киназы | |
| JP2017530190A (ja) | ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン | |
| ES2992410T3 (es) | Inhibidores cetónicos de la lisina gingipaína | |
| ES2895965T3 (es) | Moduladores del receptor de GABA(A) y métodos para controlar la hiperreactividad de las vías respiratorias y la inflamación en el asma | |
| ES3039345T3 (en) | 4,5,6,7-tetrahydro-l-benzothiophene modulators of retinoic acid receptor related (rar) orphan nuclear receptors (rors) | |
| US10538500B2 (en) | Tricyclic prodrugs | |
| EP4401739A1 (en) | Compounds, compositions and methods | |
| EP4479054A1 (en) | Compounds, compositions, and methods | |
| JP2014524448A (ja) | Ｃ型肝炎阻害化合物 | |
| ES2713775A1 (es) | Analogos no glicosidicos de alfa-galactosilceramida como activadores de celulas nkt | |
| CN113082023A (zh) | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 | |
| RU2021103834A (ru) | Соединения сульфонилмочевины в качестве ингибиторов активности интерлейкина-1 | |
| WO2026001614A1 (zh) | 一种磺酰脲类化合物及其用途 | |
| RU2019126388A (ru) | Химические соединения в качестве ингибиторов активности интерлейкина-1 |